Last reviewed · How we verify
NCT04323878: EC-COVID-PCS
Early CPAP in COVID-19 Patients With Respiratory Failure. A Prospective Cohort Study.
trial in Early CPAP Ventilation in COVID-19 Patients in 6,000 participants. Completed in 15 December 2022.
31 May 2021
Quick facts
| Lead sponsor | Mario Negri Institute for Pharmacological Research |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 6,000 |
| Start date | 1 June 2020 |
| Primary completion | 31 May 2021 |
| Estimated completion | 15 December 2022 |
| Sites | 1 location across Italy |
Conditions studied
- Early CPAP Ventilation in COVID-19 Patients — all drugs for Early CPAP Ventilation in COVID-19 Patients →
Sponsor
Mario Negri Institute for Pharmacological Research
Who can join
18 and older, any sex, with Early CPAP Ventilation in COVID-19 Patients. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This cohort study aims at prospectively collecting detailed clinical information on patients positive to or suspected of COVID-19 visiting Italian emergency departments (EDs). The objectives of the study are: 1. To monitor and describe the COVID-19 patients visiting Italian EDs. 2. To assess the prognostic impact of demographics, clinical characteristics, risk factors and pre-existing diseases. 3. To develop a predictive model, providing estimates of the prognosis using multiple relevant factors. 4. To construct a detailed database to enable comparative effectiveness research (CER), with the goal of generating hypothesis of efficacy and effectiveness of treatments, therapies and interventions, in the management and treatment of COVID-19 patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04323878
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Mario Negri Institute for Pharmacological Research trials
Trials by the same sponsor.
- NCT07428018 — Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Onco · Phase 2 · not yet recruiting
- NCT07331103 — RESOLving INflammation Through Diet for Health (RESOLVIN) · NA · recruiting
- NCT06994468 — Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy · NA · completed
- NCT07111624 — A New Crowding Indicator in the Emergency Department · not yet recruiting
- NCT07021118 — Mild TBI in the Emergency Department · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04323878 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mario Negri Institute for Pharmacological Research
- Last refreshed: 19 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04323878.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing